JP2019515652A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515652A5 JP2019515652A5 JP2018548420A JP2018548420A JP2019515652A5 JP 2019515652 A5 JP2019515652 A5 JP 2019515652A5 JP 2018548420 A JP2018548420 A JP 2018548420A JP 2018548420 A JP2018548420 A JP 2018548420A JP 2019515652 A5 JP2019515652 A5 JP 2019515652A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- scfv
- seq
- polynucleotide
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091033319 polynucleotide Proteins 0.000 claims description 66
- 102000040430 polynucleotide Human genes 0.000 claims description 66
- 239000002157 polynucleotide Substances 0.000 claims description 66
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 61
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 61
- 210000004027 cell Anatomy 0.000 claims description 52
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 39
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 37
- 102000037865 fusion proteins Human genes 0.000 claims description 35
- 108020001507 fusion proteins Proteins 0.000 claims description 35
- 201000010099 disease Diseases 0.000 claims description 26
- 230000000139 costimulatory effect Effects 0.000 claims description 24
- 230000009870 specific binding Effects 0.000 claims description 19
- 239000012636 effector Substances 0.000 claims description 18
- 208000035475 disorder Diseases 0.000 claims description 17
- 239000003550 marker Substances 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 14
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 13
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 13
- 230000027455 binding Effects 0.000 claims description 13
- 230000026683 transduction Effects 0.000 claims description 13
- 238000010361 transduction Methods 0.000 claims description 13
- 229960004641 rituximab Drugs 0.000 claims description 12
- 102100027207 CD27 antigen Human genes 0.000 claims description 10
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 10
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 10
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 10
- 230000003834 intracellular effect Effects 0.000 claims description 10
- 229950005751 ocrelizumab Drugs 0.000 claims description 10
- 229960002450 ofatumumab Drugs 0.000 claims description 10
- 229950000815 veltuzumab Drugs 0.000 claims description 10
- 206010025323 Lymphomas Diseases 0.000 claims description 9
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 8
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 8
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 8
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 8
- 206010021263 IgA nephropathy Diseases 0.000 claims description 8
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 8
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 8
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 8
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 8
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 8
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 8
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 8
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 8
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 8
- 206010010144 Completed suicide Diseases 0.000 claims description 7
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- 239000002254 cytotoxic agent Substances 0.000 claims description 6
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 230000002209 hydrophobic effect Effects 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 230000001594 aberrant effect Effects 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims description 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 4
- 208000023328 Basedow disease Diseases 0.000 claims description 4
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 208000015023 Graves' disease Diseases 0.000 claims description 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 4
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 4
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 4
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 4
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 4
- 201000003791 MALT lymphoma Diseases 0.000 claims description 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 201000002481 Myositis Diseases 0.000 claims description 4
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010036524 Precursor B-lymphoblastic lymphomas Diseases 0.000 claims description 4
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims description 4
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 4
- 201000008244 anti-basement membrane glomerulonephritis Diseases 0.000 claims description 4
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 4
- 231100000433 cytotoxic Toxicity 0.000 claims description 4
- 230000001472 cytotoxic effect Effects 0.000 claims description 4
- 210000004443 dendritic cell Anatomy 0.000 claims description 4
- 201000001981 dermatomyositis Diseases 0.000 claims description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 4
- 201000003444 follicular lymphoma Diseases 0.000 claims description 4
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 4
- 208000013643 idiopathic inflammatory myopathy Diseases 0.000 claims description 4
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims description 4
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 4
- 210000003563 lymphoid tissue Anatomy 0.000 claims description 4
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 210000001370 mediastinum Anatomy 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 210000004877 mucosa Anatomy 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 206010028417 myasthenia gravis Diseases 0.000 claims description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 4
- 208000008795 neuromyelitis optica Diseases 0.000 claims description 4
- 230000037361 pathway Effects 0.000 claims description 4
- 208000005987 polymyositis Diseases 0.000 claims description 4
- 201000008158 rapidly progressive glomerulonephritis Diseases 0.000 claims description 4
- 201000006845 reticulosarcoma Diseases 0.000 claims description 4
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims description 4
- 230000000638 stimulation Effects 0.000 claims description 4
- 230000002992 thymic effect Effects 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 claims description 2
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 claims description 2
- 101100364669 Caenorhabditis elegans lin-18 gene Proteins 0.000 claims description 2
- 102100024965 Caspase recruitment domain-containing protein 11 Human genes 0.000 claims description 2
- 108020004705 Codon Proteins 0.000 claims description 2
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims description 2
- 101000914489 Homo sapiens B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 claims description 2
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 claims description 2
- 101000761179 Homo sapiens Caspase recruitment domain-containing protein 11 Proteins 0.000 claims description 2
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 2
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 2
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 2
- 101001103033 Homo sapiens Tyrosine-protein kinase transmembrane receptor ROR2 Proteins 0.000 claims description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 2
- 101100364671 Mus musculus Ryk gene Proteins 0.000 claims description 2
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 claims description 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 2
- 102000007497 Patched-2 Receptor Human genes 0.000 claims description 2
- 108010071083 Patched-2 Receptor Proteins 0.000 claims description 2
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims description 2
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 claims description 2
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 2
- 108010023649 Tripartite Motif Proteins Proteins 0.000 claims description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 2
- 102100039616 Tyrosine-protein kinase transmembrane receptor ROR2 Human genes 0.000 claims description 2
- 239000000611 antibody drug conjugate Substances 0.000 claims description 2
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 2
- 229960003008 blinatumomab Drugs 0.000 claims description 2
- 229960005395 cetuximab Drugs 0.000 claims description 2
- 229940050282 inebilizumab-cdon Drugs 0.000 claims description 2
- 229950001603 taplitumomab paptox Drugs 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims 3
- 208000019758 Hypergammaglobulinemia Diseases 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 229940124292 CD20 monoclonal antibody Drugs 0.000 claims 1
- 239000013066 combination product Substances 0.000 claims 1
- 229940127555 combination product Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 40
- 238000009169 immunotherapy Methods 0.000 description 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021172976A JP7397840B2 (ja) | 2016-03-18 | 2021-10-22 | Ｃｄ２０免疫療法のための組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662310541P | 2016-03-18 | 2016-03-18 | |
| US62/310,541 | 2016-03-18 | ||
| US201662320327P | 2016-04-08 | 2016-04-08 | |
| US62/320,327 | 2016-04-08 | ||
| PCT/US2017/023098 WO2017161353A1 (en) | 2016-03-18 | 2017-03-17 | Compositions and methods for cd20 immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021172976A Division JP7397840B2 (ja) | 2016-03-18 | 2021-10-22 | Ｃｄ２０免疫療法のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515652A JP2019515652A (ja) | 2019-06-13 |
| JP2019515652A5 true JP2019515652A5 (enExample) | 2020-04-30 |
| JP7065782B2 JP7065782B2 (ja) | 2022-05-12 |
Family
ID=58448653
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018548420A Active JP7065782B2 (ja) | 2016-03-18 | 2017-03-17 | Ｃｄ２０免疫療法のための組成物および方法 |
| JP2021172976A Active JP7397840B2 (ja) | 2016-03-18 | 2021-10-22 | Ｃｄ２０免疫療法のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021172976A Active JP7397840B2 (ja) | 2016-03-18 | 2021-10-22 | Ｃｄ２０免疫療法のための組成物および方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10875927B2 (enExample) |
| EP (2) | EP3939994A3 (enExample) |
| JP (2) | JP7065782B2 (enExample) |
| KR (2) | KR102499191B1 (enExample) |
| CN (1) | CN108884144B (enExample) |
| AU (1) | AU2017235657B2 (enExample) |
| BR (1) | BR112018067977A8 (enExample) |
| CA (1) | CA3015369A1 (enExample) |
| DK (1) | DK3430038T3 (enExample) |
| ES (1) | ES2893840T3 (enExample) |
| IL (1) | IL261316B2 (enExample) |
| MX (1) | MX2018010415A (enExample) |
| NZ (1) | NZ744913A (enExample) |
| WO (1) | WO2017161353A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL292038B2 (en) | 2014-04-23 | 2024-12-01 | Juno Therapeutics Inc | Methods for enriching or producing immune cell populations for adoptive therapy |
| CN105985444B (zh) * | 2015-02-05 | 2024-02-13 | 博生吉安科细胞技术有限公司 | 一种嵌合抗原受体、以及快速构建嵌合抗原受体的方法及应用 |
| CN108395482B (zh) | 2017-02-08 | 2021-02-05 | 西比曼生物科技（香港）有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
| JP7357626B2 (ja) | 2017-11-01 | 2023-10-06 | ジュノー セラピューティクス インコーポレイテッド | 操作された細胞の治療用組成物を生成するためのプロセス |
| AU2018379091A1 (en) | 2017-12-08 | 2020-06-25 | Juno Therapeutics, Inc. | Serum-free media formulation for culturing cells and methods of use thereof |
| CN119193493A (zh) | 2017-12-08 | 2024-12-27 | 朱诺治疗学股份有限公司 | 生产工程化t细胞组合物的过程 |
| AU2019216269B2 (en) * | 2018-01-30 | 2025-05-01 | Cellectis | Combination comprising allogeneic immune cells deficient for an antigen present on both T-cells and pathological cells and therapeutic antibody against said antigen |
| CN112368021B (zh) | 2018-06-14 | 2025-02-21 | 2赛文缇生物公司 | Cd79a嵌合抗原受体 |
| BR112021002390A2 (pt) | 2018-08-09 | 2021-05-11 | Juno Therapeutics Inc | processos para gerar células modificadas e suas composições |
| CN109293781A (zh) * | 2018-09-12 | 2019-02-01 | 中国人民解放军总医院 | 嵌合抗原受体及其基因和重组表达载体、cd19-cd20双靶向性的t细胞及其应用 |
| CN112840026B (zh) * | 2018-10-18 | 2025-01-14 | 施能康公司 | 抑制tigit基因表达的组合物和方法 |
| KR20250116790A (ko) | 2018-12-12 | 2025-08-01 | 카이트 파마 인코포레이티드 | 키메라 항원 수용체 및 car-t 세포 및 사용 방법 |
| WO2020180648A1 (en) * | 2019-03-01 | 2020-09-10 | Gritstone Oncology, Inc. | Selection of t cell receptors |
| GB201906685D0 (en) * | 2019-05-13 | 2019-06-26 | Ultrahuman Six Ltd | Activatable protein constructs and uses thereof |
| MX2021015495A (es) * | 2019-06-14 | 2022-04-18 | 2Seventy Bio Inc | Composiciones y métodos para tratar cáncer. |
| AU2020315213A1 (en) * | 2019-07-17 | 2022-02-03 | National University Of Singapore | Functional binders synthesized and secreted by immune cells |
| US20220411479A1 (en) * | 2019-10-30 | 2022-12-29 | Precision Biosciences, Inc. | Cd20 chimeric antigen receptors and methods of use for immunotherapy |
| CN111944062B (zh) * | 2019-12-09 | 2023-11-07 | 深圳市体内生物医药科技有限公司 | 一种识别Fc片段的嵌合抗原受体及其应用 |
| KR20220149606A (ko) * | 2020-03-02 | 2022-11-08 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 암 치료를 위한 키메라 항원 수용체 및 관련 방법 및 조성물 |
| CN113402612A (zh) | 2020-03-17 | 2021-09-17 | 西比曼生物科技（香港）有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
| WO2021231959A1 (en) * | 2020-05-15 | 2021-11-18 | Precision Biosciences, Inc. | Methods for immunotherapy |
| WO2021231954A1 (en) * | 2020-05-15 | 2021-11-18 | Precision Biosciences, Inc. | Methods for immunotherapy |
| CN114774364B (zh) * | 2022-04-26 | 2024-04-26 | 深圳市体内生物医药科技有限公司 | 一种嵌合抗原受体t细胞及其制备方法和应用 |
| CN117343176A (zh) * | 2022-07-04 | 2024-01-05 | 上海优卡迪生物医药科技有限公司 | 人源化的结合cd20的抗体或cd20抗原结合片段及应用 |
| WO2024097313A1 (en) * | 2022-11-02 | 2024-05-10 | Sana Biotechnology, Inc. | Methods for producing t cell therapy products |
| PE20260290A1 (es) | 2023-03-31 | 2026-02-10 | Abelzeta Inc | Receptores de antigeno quimericos biespecificos dirigidos a cd20 y bcma |
| WO2026006767A1 (en) | 2024-06-28 | 2026-01-02 | Dispatch Biotherapeutics, Inc. | Tethered il-9/il-9r and related engineered cells and methods |
| WO2026073918A1 (en) * | 2024-10-02 | 2026-04-09 | Galapagos Nv | Novel anti-cd20 binding domains and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US6759243B2 (en) | 1998-01-20 | 2004-07-06 | Board Of Trustees Of The University Of Illinois | High affinity TCR proteins and methods |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US7514537B2 (en) | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
| EP1891113A2 (en) * | 2005-06-02 | 2008-02-27 | AstraZeneca AB | Antibodies directed to cd20 and uses thereof |
| WO2008042814A2 (en) | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
| KR20100102172A (ko) | 2007-12-21 | 2010-09-20 | 제넨테크, 인크. | 리툭시마브-난치성 류마티스성 관절염 환자의 요법 |
| KR101319499B1 (ko) | 2008-02-22 | 2013-10-17 | 엘지디스플레이 주식회사 | 화학적 자기조립 방법을 이용한 나노선 혹은탄소나노튜브의 적층 및 패턴형성 방법과, 이를 적용한액정표시장치의 제조방법 |
| CA2735456C (en) | 2008-08-26 | 2021-11-16 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| JP5956342B2 (ja) | 2009-11-03 | 2016-07-27 | シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ | 形質導入Ｔ細胞選択のためのトランケート上皮増殖因子レセプタ（ＥＧＦＲｔ） |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2012129514A1 (en) * | 2011-03-23 | 2012-09-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| EP2707723B1 (en) | 2011-05-12 | 2016-02-10 | Genentech, Inc. | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides |
| US20140004037A1 (en) | 2012-01-19 | 2014-01-02 | Therapeutic Proteins, Inc. | Stabilization of the anti-cd20 antibody rituximab |
| LT2884999T (lt) | 2012-08-20 | 2021-04-12 | Fred Hutchinson Cancer Research Center | Ląstelinės imunoterapijos būdas ir kompozicijos |
| KR102185175B1 (ko) | 2012-11-02 | 2020-12-02 | 티지 쎄라퓨틱스, 인코포레이티드 | 항cd20 항체와 pi3 키나아제 선택적 억제제의 조합물 |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| WO2015042807A1 (zh) * | 2013-09-25 | 2015-04-02 | 北京安保康生物医药科技有限公司 | 抗cd20的全人源单克隆抗体及其应用 |
| NZ759969A (en) | 2013-12-20 | 2022-12-23 | Fred Hutchinson Cancer Center | Tagged chimeric effector molecules and receptors thereof |
| JP6831777B2 (ja) * | 2014-07-21 | 2021-02-17 | ノバルティス アーゲー | Ｃｄ３３キメラ抗原受容体を使用する癌の処置 |
| CN105330750B (zh) * | 2015-11-20 | 2019-02-01 | 上海细胞治疗研究院 | 一种快速中止car-t细胞杀伤作用的分子刹车及其用途 |
-
2017
- 2017-03-17 AU AU2017235657A patent/AU2017235657B2/en active Active
- 2017-03-17 US US16/086,290 patent/US10875927B2/en active Active
- 2017-03-17 EP EP21179474.8A patent/EP3939994A3/en not_active Withdrawn
- 2017-03-17 JP JP2018548420A patent/JP7065782B2/ja active Active
- 2017-03-17 BR BR112018067977A patent/BR112018067977A8/pt not_active Application Discontinuation
- 2017-03-17 CN CN201780018083.9A patent/CN108884144B/zh active Active
- 2017-03-17 KR KR1020227005550A patent/KR102499191B1/ko active Active
- 2017-03-17 KR KR1020187026926A patent/KR102366611B1/ko active Active
- 2017-03-17 DK DK17714373.2T patent/DK3430038T3/da active
- 2017-03-17 CA CA3015369A patent/CA3015369A1/en active Pending
- 2017-03-17 MX MX2018010415A patent/MX2018010415A/es unknown
- 2017-03-17 NZ NZ744913A patent/NZ744913A/en unknown
- 2017-03-17 IL IL261316A patent/IL261316B2/en unknown
- 2017-03-17 WO PCT/US2017/023098 patent/WO2017161353A1/en not_active Ceased
- 2017-03-17 ES ES17714373T patent/ES2893840T3/es active Active
- 2017-03-17 EP EP17714373.2A patent/EP3430038B1/en active Active
-
2020
- 2020-11-24 US US17/103,762 patent/US11834511B2/en active Active
-
2021
- 2021-10-22 JP JP2021172976A patent/JP7397840B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6909844B2 (ja) | 細胞 | |
| US20240156866A1 (en) | Multifunctional immune cell therapies | |
| TWI883026B (zh) | 抗ｄｌｌ３嵌合抗原受體及其用途 | |
| Jonnalagadda et al. | Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy | |
| JP2020511529A5 (enExample) | ||
| JP2017524367A5 (enExample) | ||
| KR20190126115A (ko) | Il-12 및 il-18로의 il-15-기반 융합 | |
| WO2022125711A1 (en) | Targeted cytokine construct for engineered cell therapy | |
| CN110461335A (zh) | 用于治疗bcma相关癌症和自身免疫性失调的联合疗法 | |
| CA3030837A1 (en) | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor | |
| CN106922147A (zh) | Cd19特异性抗体和嵌合抗原受体 | |
| JP2016514462A5 (enExample) | ||
| US20220047636A1 (en) | Chimeric antigen receptors targeting cd79b and cd19 | |
| JP2019512215A (ja) | 改変細胞及び方法 | |
| JP2025107358A (ja) | 細胞 | |
| CA3063169A1 (en) | T cells expressing a chimeric antigen receptor | |
| US20240307439A1 (en) | Multifunctional immune cell therapies | |
| WO2023000170A1 (en) | Cd147 antibodies and cd147-car-t cells | |
| JP2023535485A (ja) | 抗ｃｄ２２シングルドメイン抗体および治療用コンストラクト | |
| RU2018134300A (ru) | Композиции и способы иммунотерапии против cd20 | |
| NZ786254A (en) | Compositions and methods for cd20 immunotherapy | |
| WO2026042055A1 (en) | Dual targeting cancer cell therapy for cd19 and cd20 | |
| CN121532497A (zh) | Cldn18.2和gucy2c靶向拮抗剂组合疗法 | |
| CN116157415A (zh) | 靶向抗rh抗体的组合物和方法 |